
Wednesday, March 15, 2023
6:45am | Registration / Continental Breakfast | |
Vaquero Ballroom Foyer | ||
7:20am | Welcome and Opening Remarks | |
Mykl Garrett, Associate Vice President, HonorHealth Cardiovascular Service Line | ||
Arizona Ballroom, Level 1 | ||
Cases Over Coffee I: Case Presentation and Expert CommentaryModerator: Michael A. Kutcher, MD | ||
7:30 am | Case 1: PASCAL Case | |
Molly Szerlip, MD | ||
7:40 am | Case 2: Mitral Therapies Through the Lens of Advanced Echocardiographic Imaging | |
Robert F. Burke, MD | ||
7:50 am | Case 3: TAVR Shock in Severely Calcified Valve | |
M. Chadi Alraies, MD | ||
Structural Heart Therapies Session IModerator: Jonathon Leipsic, MD; Michael J. Rinaldi, MD | ||
8:00 am | Top Structural Trials of the Last Year | |
Michael J. Reardon, MD | ||
8:15 am | Expanding the Indications for Left Atrial Appendage Mechanical Therapies | |
Srinivas Iyengar, MD | ||
8:30 am | Amulet Adoption: How Fast, How Far? | |
Neil M. Gheewala, MD | ||
8:45 am | Long-Term Watchman Safety and Durability | |
Ronald Caputo, MD | ||
Live Cases 1 & 2 | LAA and MITRALModerators: Jonathon Leipsic, MD and Michael J. Rinaldi, MD | ||
9:00 am | Case 1 | |
Broadcast from HonorHealth Shea Medical Center, Scottsdale, Arizona | ||
Operator: Alok Sharma, MD and Rahul N. Doshi, MD | ||
9:30 am | Case 2 | |
Broadcast from HonorHealth Shea Medical Center, Scottsdale, Arizona | ||
Operator: Robert D. Riley, MD; David G. Rizik, MD | ||
10:00am | Break / Visit Exhibits | |
Structural Heart Therapies IIModerators: Gregg W. Stone, MD and Steven J. Yakubov, MD | ||
10:30 am | The Mitral Valve is Complex; Don’t Make It More Complex | |
Kendra Grubb, MD | ||
10:45 am | Cardiac Computed Tomography and Magnetic Resonance Imaging in the Evaluation of Mitral and Tricuspid Valve Disease: Implications for Transcatheter Interventions | |
Jonathon Leipsic, MD | ||
11:00 am | The Evolution of Your TEER Program: From Basic to Complex Cases | |
Steven J. Yakubov, MD | ||
11:15 am | TEER in FMR: Durable Therapy or Band Aid on a Much Larger Wound? | |
Gregg W. Stone, MD | ||
11:30 am | EVEREST II and PRIMARY: Should Degenerative MR Patients Have a Choice to Trial TEER Prior to Surgery? | |
Michael J. Rinaldi, MD | ||
11:45 am | The Emerging Role of Supported Mitral Interventions | |
David G. Rizik, MD | ||
12:00 pm | LUNCH / VISIT EXHIBITS | |
Pick-Up Lunch and Return to the Ballroom | ||
Working Lunch: Structural Heart Therapies III: Emerging Tricuspid Catheter-Based TherapiesModerators: Paul Sorajja, MD and TBD | ||
12:30 pm | Landscape of Emerging Tricuspid Valve Therapies | |
Mark Reisman, MD | ||
12:45 pm | Tricuspid TEER: Shortcuts and Simplification for the Interventionalists | |
James M. McCabe, MD | ||
1:00 pm | Why Tricuspid Valve TEER is Our Future: And, Here’s Some of My Best Cases to Prove It | |
Megan Coylewright, MD | ||
1:15 pm | Patient Selection for Tricuspid TEER: Defining Severe TR by Echo in our Trials? | |
Paul Sorajja, MD | ||
Live Cases 3 & 4 | LAA/TAVR/MITRAL/PFOModerators: Steven R. Bailey, MD and Steven J. Yakubov, MD | ||
1:30 pm | Case 3 | |
Broadcast from Henry Ford Hospital, Detroit Michigan | ||
Operator: William W. O'Neill, MD | ||
2:15 pm | Case 4 | |
Broadcast from HonorHealth Shea Medical Center, Scottsdale, Arizona | ||
Operators: Robert D. Riley, MD; David G. Rizik, MD | ||
Guest Operator: Mark Reisman, MD | ||
Structural Heart Therapies IV | Mitral Replacement Therapies: Cephea, APOLLO, Tendyne, etc.Moderators: Molly Szerlip, MD and Steven J. Yakubov, MD | ||
3:00 pm | Neo-LVOT and Transcatheter Mitral Valve Replacement: Expert Recommendations | |
Jonathon Leipsic, MD | ||
3:15 pm | Tendyne and Cephea Programs Update | |
Paul Sorajja, MD | ||
3:30 pm | Intrepid and Evoque Program Updates | |
James B. Hermiller, MD | ||
3:45 pm | Mitral Valve-in-Valve and Valve-in-Ring: Tips & Tricks, Case Selection | |
Adam B. Greenbaum, MD | ||
4:00 pm | Break / Grab a Cocktail | |
Controversies Over CockatilsModerators: James B. Hermiller, MD; Mark Reisman, MD; Robert D. Riley, MD; David G. Rizik, MD | ||
TAVR Durability | ||
4:20 pm | TAVR Durability is Sufficient: Most 60-Year-Old Patients Should Get TAVR | |
John M. Lasala, MD, PhD | ||
4:28 pm | TAVR Durability Is Still in Doubt: SAVR Remains Best Therapy for 60-Year-Old Patients | |
Katherine B. Harrington, MD | ||
4:36 pm | Discussion | |
Single-Operator TAVR | ||
4:40 pm | Let’s Make TAVR a Single-Operator Procedure | |
Ashish Pershad, MD | ||
4:48 pm | That’ll Be a Huge Mistake!!! | |
Kendra Grubb, MD | ||
4:56 pm | Discussion | |
Cerebral Embolic Protection | ||
5:00 pm | The Data for Cerebral Embolic Protection Justifies Its Use in All TAVR Cases | |
Steven J. Yakubov, MD | ||
5:08 pm | Protected TAVR Was Negative: The Data Does Not Justify CEP Use in All TAVR Cases | |
David A. Cox, MD | ||
5:16 pm | Discussion and Closing Remarks |